For following the competition: what moved in each program, several studies read as one move.
- blinatumomab
- Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890
- cytokine-induced killer cell
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Neoplasm, Residual to watchlistEvery Monday by email · turn it off any timePro · free during the beta